

# Max Sauter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9563961/publications.pdf>

Version: 2024-02-01

29  
papers

331  
citations

1040018

9  
h-index

888047

17  
g-index

29  
all docs

29  
docs citations

29  
times ranked

473  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiolabeling Strategies for Tumor-Targeting Proteinaceous Drugs. <i>Molecules</i> , 2014, 19, 2135-2165.	3.8	48
2	Comparison of the RGD Motifâ€‘Containing Î± <sub>v</sub> Î² <sub>6</sub> Integrinâ€‘Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1679-1685.	5.0	38
3	Identification of a Novel ITCÎ±vÎ²6-Binding Peptide Using Protein Separation and Phage Display. <i>Clinical Cancer Research</i> , 2017, 23, 4170-4180.	7.0	37
4	Delivery of Copper-chelating Trientine (TETA) to the central nervous system by surface modified liposomes. <i>International Journal of Pharmaceutics</i> , 2016, 512, 87-95.	5.2	33
5	Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery. <i>Journal of Controlled Release</i> , 2020, 322, 200-208.	9.9	30
6	PET/CT Imaging of NSCLC with a Î±vÎ²6 Integrin-Targeting Peptide. <i>Molecular Imaging and Biology</i> , 2019, 21, 973-983.	2.6	21
7	Overcoming the Mucosal Barrier: Tetraether Lipidâ€‘Stabilized Liposomal Nanocarriers Decorated with Cellâ€‘Penetrating Peptides Enable Oral Delivery of Vancomycin. <i>Advanced Therapeutics</i> , 2021, 4, 2000247.	3.2	16
8	High treatment efficacy by dual targeting of Burkittâ€™s lymphoma xenografted mice with a <sup>177</sup> Lu-based CD22-specific radioimmunoconjugate and rituximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 489-498.	6.4	13
9	Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. <i>Bioanalysis</i> , 2019, 11, 1459-1467.	1.5	12
10	Development and Validation of an LCâ€‘MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. <i>ACS Omega</i> , 2020, 5, 24329-24339.	3.5	10
11	An ultrasensitive UPLCâ€‘MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. <i>Bioanalysis</i> , 2019, 11, 887-898.	1.5	9
12	An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 633-638.	2.8	8
13	Preclinical evaluation of peptide-based radiotracers for integrin Î±vÎ²6-positive pancreatic carcinoma. <i>Nuklearmedizin - Nuclear Medicine</i> , 2019, 58, 309-318.	0.7	8
14	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2090-2094.	3.3	6
15	Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. <i>Journal of Pharmaceutical Analysis</i> , 2020, 10, 233-239.	5.3	5
16	Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. <i>Analytica Chimica Acta</i> , 2020, 1114, 42-49.	5.4	5
17	Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5645-5654.	3.7	4
18	Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3637.	4.1	4

#	ARTICLE	IF	CITATIONS
19	Preclinical evaluation of a diabody-based <sup>177</sup> Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model. <i>Cancer Letters</i> , 2016, 381, 296-304.	7.2	3
20	Reporter cell assay-based functional quantification of TNF- $\alpha$ -antagonists in serum – a proof-of-principle study for adalimumab. <i>Analytical Biochemistry</i> , 2020, 596, 113646.	2.4	3
21	Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides – Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 194, 113728.	2.8	3
22	Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. <i>Pharmaceutics</i> , 2021, 13, 1019.	4.5	3
23	Effect of Pantoprazole on the Absorption of Hydroxychloroquine A Randomized Drug-Drug Interaction Trial in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 285-290.	1.6	3
24	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. <i>Pharmaceutics</i> , 2021, 13, 1498.	4.5	3
25	An Underestimated Factor: The Extent of Cross-Reactions Modifying APIs in Surface-Modified Liposomal Preparations Caused by Comprised Activated Lipids. <i>Molecules</i> , 2020, 25, 4436.	3.8	2
26	Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 186, 113276.	2.8	2
27	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1176, 122781.	2.3	2
28	Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue. <i>Pharmaceutics</i> , 2022, 14, 762.	4.5	0
29	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. <i>Neuro-Oncology</i> , 2022, 24, i93-i93.	1.2	0